Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic

Cagrilintide

$85.00 – $109.00 Select options

Cagrilintide

Price range: $85.00 through $109.00

Cagrilintide is an investigational long-acting amylin receptor agonist developed by Novo Nordisk as the first once-weekly amylin analog.

Size: No selection

More options

Clear

Cagrilintide is an investigational long-acting amylin receptor agonist developed by Novo Nordisk as the first once-weekly amylin analog. It mimics the pancreatic hormone amylin to reduce food intake, delay gastric emptying, and enhance satiety via activation of calcitonin/amylin receptors in the area postrema and hypothalamus. When combined with GLP-1 agonists (e.g., semaglutide in CagriSema), it produces additive weight loss and superior glycemic control. Currently in Phase 3 (REDEFINE program) for obesity and diabetes, with Phase 2 data showing up to −15.6% body weight loss at 52 weeks (4.5 mg dose). This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation.

Key Scientific

High-purity Cagrilintide (≥ 98% by HPLC/MS, acetate salt form)
Verified 37-amino-acid sequence with C14 fatty diacid lipidation at Lys²
Lyophilized formulation for maximum long-term stability
Full Certificate of Analysis (COA) with HPLC, MS, lipidation verification, and receptor-binding data
Manufactured in GMP-aligned, ISO-compliant facilities
Ideal for amylin receptor, energy homeostasis, and combination incretin research

Research-Referenced Attributes (Based on published clinical/preclinical literature; not therapeutic claims.)

Once-weekly dosing with half-life ~200 hours (vs. pramlintide’s 45 minutes)
Phase 2 monotherapy: −10.8% to −15.6% weight loss at 52 weeks (dose-dependent 0.3–4.5 mg)
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg): −22.7% weight loss at 68 weeks (vs. −15.6% semaglutide alone)
Superior gastric emptying delay and satiety vs. GLP-1 alone
Significant HbA1c reduction (−2.2%) and fasting glucose improvement
Favorable lipid profile and blood pressure lowering
Valuable in obesity, T2D, NAFLD, and combination incretin research

Why Researchers Choose Nationwide Peptides Cagrilintide

Exact clinical-sequence match to NNC0174-0833 with correct C14 lipidation
Highest documented AMYR affinity and half-life among research suppliers
Transparent analytical data (HPLC >98%, MS confirmation of lipidated structure)
Trusted by metabolic disease, obesity, and incretin pharmacology laboratories
Competitive research pricing with bulk options

Storage & Handling

Store lyophilized powder at –4 °F (long-term) or 39.2 °F (short-term)
Store in a tightly sealed container and protect from light, moisture, air exposure, and elevated temperatures.
Reconstitute only with bacteriostatic water or sterile saline (typical concentration 5–10 mg/mL)
Reconstituted solutions stable at 39.2 °F for up to 4 weeks; avoid repeated freeze-thaw cycles